Novogene Co., Ltd. (SHA:688315)
14.34
-0.34 (-2.32%)
Sep 2, 2026, 3:00 PM CST
Novogene Revenue
Novogene had revenue of 557.40M CNY in the quarter ending June 30, 2026, with 3.59% growth. This brings the company's revenue in the last twelve months to 2.28B, up 5.97% year-over-year. In the year 2025, Novogene had annual revenue of 2.21B with 4.66% growth.
Revenue (ttm)
2.28B
Revenue Growth
+5.97%
P/S Ratio
2.60
Revenue / Employee
1.03M
Employees
2,225
Market Cap
5.95B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.21B | 98.32M | 4.66% |
| Dec 31, 2024 | 2.11B | 109.21M | 5.45% |
| Dec 31, 2023 | 2.00B | 76.47M | 3.97% |
| Dec 31, 2022 | 1.93B | 59.24M | 3.17% |
| Dec 31, 2021 | 1.87B | 376.37M | 25.26% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Youcare Pharmaceutical Group | 2.46B |
| Chengdu Kanghua Biological Products | 1.22B |
| Shenzhen Weiguang Biological Products | 1.20B |
| Boji Medical Technology | 961.34M |
| R&G PharmaStudies | 939.31M |
| Wuhan Keqian Biology Co.,Ltd | 836.28M |
| Zhejiang Ausun Pharmaceutical | 778.50M |
| Jiangsu Aidea Pharmaceutical Group | 722.54M |